About Michelson Diagnostics
Michelson Diagnostics (MDL) is a UK-based independent company with products based on an optical imaging technology, called 'Multi-Beam OCT'. The company is primarily targeting cancer (screening, diagnosis, staging, treatment planning and guidance, and monitoring), but the products are also finding applications in commercial skin products research, in genetics (developmental biology) and in industrial metrology.
Missing: Michelson Diagnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Michelson Diagnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Michelson Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Michelson Diagnostics is included in 5 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Michelson Diagnostics Patents
Michelson Diagnostics has filed 1 patent.
Dermal and subcutaneous growths, Angiology, Rare diseases, Vascular diseases, Laser medicine
Dermal and subcutaneous growths, Angiology, Rare diseases, Vascular diseases, Laser medicine
Latest Michelson Diagnostics News
Nov 21, 2022
News Provided By Share This Article Skin Biopsy Segment by Screening Type to Lead Skin Cancer Diagnostics Market during 2021–2028 NEW YORK, UNITED STATES, November 21, 2022 / EINPresswire.com / -- Skin cancer means abnormal growth of skin cells. It develops in the areas exposed to the sun. Ultraviolet radiation changes the genetic material (DNA) in cells and is the leading cause of skin cancer. There are two main categories of skin cancer such as melanoma and non-melanoma. Various imaging solutions such as CT scans, MRIs, PET scans, bone scans, and chest X-rays are used to diagnose skin cancer. The skin cancer diagnostics market also includes various diagnostics and therapies related to skin cancer, such as chemotherapy, targeted therapy, immunotherapy, radiotherapy, freezing treatment, and scraping therapy that helps cure skin cancer. Skin Cancer Diagnostics market size is projected to reach US$ 3,730.12 million by 2028 from US$ 2,309.60 million in 2021; it is estimated to grow at a CAGR of 7.1% from 2021 to 2028. Download PDF Brochure of this Report: https://www.theinsightpartners.com/sample/TIPRE00018116/ Leading companies operating in the market have undertaken various organic growth strategies in the market. The skin cancer diagnostics market is majorly comminated by SkylineDx BV; AMLo Biosciences Limited; NeraCare GmbH; DermLite LLC; bioMerieux SA; Veriskin Inc.; Castle Biosciences, Inc.; DermTech Inc.; F. Hoffmann-La Roche Ltd., and Michelson Diagnostics Ltd. The companies have been implementing various strategies that have helped their growth and, in turn, brought about several breakthroughs and transitions in the industry. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the market players have also deployed several utilized inorganic strategies, including mergers & acquisitions, partnerships, and collaborations. Below are the major growth strategies undertaken by the players operating in the global skin cancer diagnostics market: In February 2022, Castle Biosciences, Inc. has announced the collaboration with National Cancer Institute (NCI) to link DecisionDx-Melanoma testing data with data from the Surveillance, Epidemiology and End Results (SEER) Program’s registries on cutaneous melanoma (CM) cases. The analysis of the first subset of linked SEER patient data demonstrates DecisionDx-Melanoma testing was associated with improved overall survival rates compared to untested patients In April 2021, Castle Biosciences, Inc. has signed a definitive agreement to acquire all of the equity of Myriad myPath, LLC (Myriad myPath Laboratory), from Myriad Genetics for $32.5 million. After this acquisition Castle strategically expands its suite of genomic tests for skin cancer and expects to offer the most comprehensive testing solution for difficult-to-diagnose melanocytic lesions. In June 2021, AI specialists Manchester Imaging Ltd have won a UK Innovation Scholars grant to support the parttime secondment of AI expert Tom Williams to skin scanner specialists Michelson Diagnostics Ltd over two years. It will process images of basal cell carcinoma, the most common form of skin cancer affecting millions worldwide, scanned by dermatologists using the innovative VivoSight OCT scanner already manufactured by Michelson Diagnostics. In April 2020, The company had announced that Merlin Assay for melanoma is officially added to their test menu and available as Laboratory Developed Test from their CAP/CLIA lab. The Merlin Assay is the first diagnostic test that resulted from the Falcon R&D Program, an R&D centered partnership with clinicians and academia, aimed at the development of tools to optimize the clinical pathway of melanoma patients The increasing incidence of skin cancer and launch of new products drive the market growth. However, the tedious and barriers to early skin cancer diagnostics in low and middle-income countries hampers the market growth. Based on screening type, the global skin cancer diagnostics market is segmented into blood tests, dermatoscopy, imaging tests, lymph node biopsy, and skin biopsy. The skin biopsy segment held the largest market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Access Full Copy of this Report: https://www.theinsightpartners.com/buy/TIPRE00018116/ About Us: The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc. Contact Us:
Michelson Diagnostics Frequently Asked Questions (FAQ)
When was Michelson Diagnostics founded?
Michelson Diagnostics was founded in 2006.
Where is Michelson Diagnostics's headquarters?
Michelson Diagnostics's headquarters is located at 1 Grays Farm Production Village, Kent.
What is Michelson Diagnostics's latest funding round?
Michelson Diagnostics's latest funding round is Series B - II.
How much did Michelson Diagnostics raise?
Michelson Diagnostics raised a total of $15.48M.
Who are the investors of Michelson Diagnostics?
Investors of Michelson Diagnostics include Octopus Ventures, Smith & Nephew, Kent County Council, Newable Ventures, Catapult Ventures and 6 more.
Who are Michelson Diagnostics's competitors?
Competitors of Michelson Diagnostics include Dilon Technologies, CivaTech Oncology, Ikonisys, Upromise, Seno Medical Instruments and 12 more.
Compare Michelson Diagnostics to Competitors
Micrima is a Bristol-based company developing a safe, low-cost system to improve the detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms.
Halo Healthcare, formerly NeoMatrix, develops devices that allow women and doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test, is a fully automated, non-invasive breast cancer risk assessment device designed for use in the primary care setting as part of an annual well-woman visit. The HALO Breast Pap Test is FDA approved for the collection of nipple aspirate fluid for cytological evaluation. The collected fluid can be used in the determination and/or differentiation of normal versus pre-malignant versus malignant cells.
Manoa Medical develops an advanced method of diagnosis and treatment of breast cancer.
FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.
CT Atlantic is an early stage company focused on the identification and development of human oncology
Orison Corporation was founded to design, manufacture and market a ultrasound technology platform for early breast cancer detection and diagnosis. Orison's technology aims to utilize Full Field Digital Ultrasound (FDDU) as an enabler that aims to allow the radiologist, for a time, to view breast tissue in a three dimensional environment. The outcome is earlier detection of breast cancer prior to metastasis, resulting in greater five-year survival rates and decreased treatment costs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.